SEC Form 4 · accession 0001144204-18-064922
ACURA PHARMACEUTICALS, INC · ACUR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert B Jones
Officer — President & CEO
Period of report
Dec 11, 2018
Accepted (ET)
Dec 17, 2018 · 4:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000786947
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F4,F2,F3 | $0.01 | Dec 11, 2018 | A | 150,000 | A | — | — | Common Stock | 150,000 | 150,000 | D |
| Stock OptionF5,F4,F6,F7 | $0.151 | Dec 11, 2018 | A | 50,000 | A | Dec 11, 2019 | Dec 11, 2023 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1Awarded under the Acura Pharmaceuticals Inc. 2017 Restricted Stock Unit Award Plan (the "Plan").
- F2Par value of $.01 must be paid by Reporting Person upon exchange of Restricted Stock Units for stock.
- F3100% of Restricted Stock Units vest on December 11, 2019 or earlier if Reporting Person's service as an employee of Issuer is terminated by Issuer without Cause (as defined in the Plan) or due to Reporting Person's death or Disability (as defined in the Plan) or a qualifying change of control occurs. Distributions in respect of vested Restricted Stock Units will be made in three equal installments on the first business day of each of January 2021, 2022, and 2023 or earlier upon a qualifying change of control which also meets certain criteria of Section 409A of the Internal Revenue Code.
- F4Not Applicable.
- F5Awarded under the Acura Pharmaceuticals Inc. 2016 Stock Option Plan.
- F6Exercise price is closing price of Issuer's common stock on December 11, 2018.
- F7Option vesting and exercisability is accelerated upon a qualifying change of control.